Öjlert ÅK - Search Results

1

The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery.

Öjlert ÅK, Halvorsen AR, Nebdal D, Lund-Iversen M, Solberg S, Brustugun OT, Lingjaerde OC, Helland Å. Öjlert ÅK, et al. Mol Oncol. 2019 May;13(5):1166-1179. doi: 10.1002/1878-0261.12475. Epub 2019 Apr 10. Mol Oncol. 2019. PMID: 30854794 Free PMC article. Clinical Trial.

2

Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC.

Halvorsen AR, Ragle Aure M, Õjlert ÅK, Brustugun OT, Solberg S, Nebdal D, Helland Å. Halvorsen AR, et al. Among authors: ojlert ak. Mol Oncol. 2019 Dec;13(12):2604-2615. doi: 10.1002/1878-0261.12571. Epub 2019 Sep 22. Mol Oncol. 2019. PMID: 31505091 Free PMC article.

3

Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients.

Halvorsen AR, Haugen MH, Öjlert ÅK, Lund-Iversen M, Jørgensen L, Solberg S, Mælandsmo GM, Brustugun OT, Helland Å. Halvorsen AR, et al. Among authors: ojlert ak. Front Oncol. 2020 Nov 25;10:590755. doi: 10.3389/fonc.2020.590755. eCollection 2020. Front Oncol. 2020. PMID: 33324562 Free PMC article.

4

Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy.

Öjlert ÅK, Nebdal D, Lund-Iversen M, Åstrøm Ellefsen R, Brustugun OT, Gran JM, Halvorsen AR, Helland Å. Öjlert ÅK, et al. Acta Oncol. 2021 Feb;60(2):149-156. doi: 10.1080/0284186X.2020.1854851. Epub 2020 Dec 24. Acta Oncol. 2021. PMID: 33356733

5

Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor.

Öjlert ÅK, Nebdal D, Snapkov I, Olsen V, Kidman J, Greiff V, Chee J, Helland Å. Öjlert ÅK, et al. Mol Oncol. 2021 Nov;15(11):2958-2968. doi: 10.1002/1878-0261.13082. Epub 2021 Sep 1. Mol Oncol. 2021. PMID: 34402187 Free PMC article.

6

Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial.

Horndalsveen H, Alver TN, Dalsgaard AM, Rogg LV, Helbekkmo N, Grønberg BH, Halvorsen TO, Ramberg C, Haakensen VD, Öjlert ÅK, Bjaanaes MM, Helland Å. Horndalsveen H, et al. Among authors: ojlert ak. Mol Oncol. 2023 Mar;17(3):487-498. doi: 10.1002/1878-0261.13330. Epub 2022 Nov 22. Mol Oncol. 2023. PMID: 36330681 Free PMC article. Clinical Trial.

7

UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial.

Haakensen VD, Öjlert ÅK, Thunold S, Farooqi S, Nowak AK, Chin WL, Grundberg O, Szejniuk WM, Cedres S, Sørensen JB, Dalen TS, Lund-Iversen M, Bjaanæs M, Helland Å. Haakensen VD, et al. Among authors: ojlert ak. Eur J Cancer. 2024 May;202:113973. doi: 10.1016/j.ejca.2024.113973. Epub 2024 Mar 1. Eur J Cancer. 2024. PMID: 38447379 Free article. Clinical Trial.

8

Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine.

Thunold S, Hernes E, Farooqi S, Öjlert ÅK, Francis RJ, Nowak AK, Szejniuk WM, Nielsen SS, Cedres S, Perdigo MS, Sørensen JB, Meltzer C, Mikalsen LTG, Helland Å, Malinen E, Haakensen VD. Thunold S, et al. Among authors: ojlert ak. Eur J Nucl Med Mol Imaging. 2024 Aug 12. doi: 10.1007/s00259-024-06853-0. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 39133306

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters